# Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

> **NCT01494740** · PHASE2 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 312 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** split-virion, non-adjuvanted vaccine of 7.5 μg
- **BIOLOGICAL:** split-virion, non-adjuvanted H1N1 vaccine of 15 μg
- **BIOLOGICAL:** split-virion, non-adjuvanted vaccine of seasonal influenza

## Key facts

- **NCT ID:** NCT01494740
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2011-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01494740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01494740, "Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01494740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*